Regeneron says potential Covid-19 drugs could start human tests by early summer
The biotechnology firm Regeneron said it has now developed hundreds of potential medicines that could work against the novel coronavirus that causes Covid-19, and that it may enter clinical trials by early summer.
Regeneron’s drugs are what are known as monoclonal antibodies, proteins produced by the immune system that can neutralize pathogens. Regeneron’s antibodies are made in mice that have been genetically modified to have human-like immune systems, which means that, when they are given to a patient, his or her immune system will not attack the antibody.
